Show simple item record

dc.contributor.authorRampal, P.
dc.contributor.authorMartin, C.
dc.contributor.authorMarquis, P.
dc.contributor.authorWare, John E. Jr.
dc.contributor.authorBonfils, S.
dc.date2022-08-11T08:10:40.000
dc.date.accessioned2022-08-23T17:16:21Z
dc.date.available2022-08-23T17:16:21Z
dc.date.issued1994-01-01
dc.date.submitted2010-06-18
dc.identifier.citationScand J Gastroenterol Suppl. 1994;206:44-51. <a href="http://dx.doi.org/10.3109/00365529409091421">Link to article on publisher's site</a>
dc.identifier.issn0085-5928 (Linking)
dc.identifier.doi10.3109/00365529409091421
dc.identifier.pmid7863253
dc.identifier.urihttp://hdl.handle.net/20.500.14038/47378
dc.description.abstractQuality of life (QoL) is commonly assessed for evaluating the process and outcome of treatment but has not been studied in duodenal ulcer (DU) disease. The recently developed and validated Quality of Life in Duodenal Ulcer Patients (QLDUP) questionnaire allowed the study of various dimensions according to treatment regimens. This study was conducted to compare QoL over a one-year follow-up period in DU patients randomized to two treatment regimens: maintenance versus intermittent (no maintenance) treatment with nizatidine. A total of 581 patients with endoscopic evidence of DU healing were randomly allocated to receive either nizatidine 150 mg/day for one year (Group A) or intermittent treatment (Group B). In both groups, symptomatic relapses were treated with nizatidine 300 mg/day for 6 weeks. The QLDUP questionnaire, which provides a QoL profile from 54 items divided up into 15 dimensions, was completed by all patients at entry and again at the time of a visit every 2 months for one year. The one-year symptomatic relapse rates were 8.0% and 33.5% in Group A and Group B, respectively (p < 0.001). The intent-to-treat analysis showed that patients in Group A had better QoL scores than those in Group B as regards 8 QoL dimensions, including ulcer-specific and non-specific dimensions. Differences between treatments were significant after 4 months, and this was sustained until the one-year assessment. The overall gain in QoL was significantly greater in Group A than in Group B with respect to 11 QoL dimensions. In conclusion, maintenance treatment with nizatidine for DU improved QoL to a larger extent than when intermittent therapy was used.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=7863253&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://dx.doi.org/10.3109/00365529409091421
dc.subjectAdult
dc.subjectDrug Administration Schedule
dc.subjectDuodenal Ulcer
dc.subjectFemale
dc.subjectHumans
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectNizatidine
dc.subject*Quality of Life
dc.subjectQuestionnaires
dc.subjectRecurrence
dc.subjectBiostatistics
dc.subjectEpidemiology
dc.subjectHealth Services Research
dc.titleA quality of life study in five hundred and eighty-one duodenal ulcer patients. Maintenance versus intermittent treatment with nizatidine
dc.typeJournal Article
dc.source.journaltitleScandinavian journal of gastroenterology. Supplement
dc.source.volume206
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/qhs_pp/517
dc.identifier.contextkey1363351
html.description.abstract<p>Quality of life (QoL) is commonly assessed for evaluating the process and outcome of treatment but has not been studied in duodenal ulcer (DU) disease. The recently developed and validated Quality of Life in Duodenal Ulcer Patients (QLDUP) questionnaire allowed the study of various dimensions according to treatment regimens. This study was conducted to compare QoL over a one-year follow-up period in DU patients randomized to two treatment regimens: maintenance versus intermittent (no maintenance) treatment with nizatidine. A total of 581 patients with endoscopic evidence of DU healing were randomly allocated to receive either nizatidine 150 mg/day for one year (Group A) or intermittent treatment (Group B). In both groups, symptomatic relapses were treated with nizatidine 300 mg/day for 6 weeks. The QLDUP questionnaire, which provides a QoL profile from 54 items divided up into 15 dimensions, was completed by all patients at entry and again at the time of a visit every 2 months for one year. The one-year symptomatic relapse rates were 8.0% and 33.5% in Group A and Group B, respectively (p < 0.001). The intent-to-treat analysis showed that patients in Group A had better QoL scores than those in Group B as regards 8 QoL dimensions, including ulcer-specific and non-specific dimensions. Differences between treatments were significant after 4 months, and this was sustained until the one-year assessment. The overall gain in QoL was significantly greater in Group A than in Group B with respect to 11 QoL dimensions. In conclusion, maintenance treatment with nizatidine for DU improved QoL to a larger extent than when intermittent therapy was used.</p>
dc.identifier.submissionpathqhs_pp/517
dc.contributor.departmentDepartment of Quantitative Health Sciences
dc.source.pages44-51


This item appears in the following Collection(s)

Show simple item record